Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gynecologic 2Gastrointestinal 1Dermatologic 1

Conditions

Rectal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Oxaliplatin 1409Fluorouracil 1298Capecitabine 1085Gemcitabine 1042Leucovorin 928Irinotecan 815Bevacizumab 803Cisplatin 666Radiotherapy 535Cetuximab 469pembrolizumab 428Paclitaxel 389Nivolumab 336130-nm albumin-bound paclitaxel 322Drug Therapy 314Docetaxel 286S 1 (combination) 273Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 209Surgical Procedures, Operative 203tislelizumab 202Radiosurgery 202lenvatinib 201apatinib 198Carboplatin 186Magnetic Resonance Spectroscopy 181regorafenib 180

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Methylation × Gastrointestinal × Clear all
NCT01850654 2018-06-28

OCCPI

Ohio State University Comprehensive Cancer Center

Phase NA Completed
3,470 enrolled
GastrointestinalGynecologic

Colonic Neoplasms, Colorectal Neoplasms, Hereditary Nonpolyposis, Rectal Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡